PR
VERA icon

PSP Research’s Vera Therapeutics VERA Stock Holding History

PSP Research’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300K Sell
7,000
-3,000
-30% -$112K 0.16% 49
2026
Q1 		$402K Buy
10,000
+4
+0% +$172 0.28% 47
2025
Q4 		$506K Buy
+9,996
New +$355K 0.44% 73

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PSP Research's VERA Position: Q2 2026 in Review

PSP Research reduced its Vera Therapeutics (VERA) stake by 30% in Q2 2026, selling an estimated $112K and leaving 7,000 shares worth $300K. The position accounts for 0.16% of the portfolio, ranked #49.

PSP Research first reported a position in VERA in Q4 2025 and has held it in 3 quarters since. The position peaked at $506K in Q4 2025. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • PSP Research held 7,000 shares of Vera Therapeutics worth $300K as of Q2 2026.
  • PSP Research sold 3,000 Vera Therapeutics shares in Q2 2026, an estimated $112K.
  • Vera Therapeutics made up 0.16% of PSP Research's portfolio in Q2 2026, its #49 holding.
  • PSP Research first reported a position in Vera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Vera Therapeutics position peaked at $506K in Q4 2025.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.